US-CONGRESS BILLS-119s4994is: Our Nation’s Supply chain for Healthcare has Over Reliance Elsewhere Act; ONSHORE Manufacturing Act
The ONSHORE Manufacturing Act (S. 4994) proposes to reduce reliance on foreign pharmaceutical supply chains by incentivizing domestic production of APIs and finished drugs, with potential impacts on FDA approval processes, DEA quotas, and drug shortage mitigation. The bill is in early stages but signals a shift toward reshoring.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 21, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; bill is in early legislative stage. Monitor for committee hearings and markups.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Introduction of a bill that would require FDA to prioritize domestic manufacturing for drug approvals and establish new incentives for onshore production, potentially affecting supply chain strategies and regulatory timelines.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Monitor bill progress; assess current supply chain exposure to foreign sources; prepare for potential changes in FDA guidance on domestic manufacturing preferences.
Deadline
No immediate deadline; bill is in early legislative stage. Monitor for committee hearings and markups.
Source: https://www.govinfo.gov/app/details/BILLS-119s4994is
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS BILLS-119hr9774ih: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
- US-CONGRESS BILLS-119hr9790ih: Modernizing Opioid Treatment Access Act 2.0 of 2026
- US-CONGRESS BILLS-119s4987is: Pharmaceutical Investment Oversight and Accountability Act
- FDA Presses Forward on Patient-Focused Drug Development, Releases Final Guidance Focused on Fit-For-Purpose Clinical Outcome Assessments - akingump.com
- CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRA - fda.gov